Seminars in nephrology最新文献_第10页

Teaching Conservative Kidney Management and Other Palliative Care Skills in Nephrology Fellowships 在肾病学奖学金中教授保守性肾脏管理和其他姑息治疗技能。

IF 3.3 3区医学

Seminars in nephrology Pub Date : 2023-01-01 DOI: 10.1016/j.semnephrol.2023.151396

Amanda K. Leonberg-Yoo MD, MS , Scott J. Gilbert MD

{"title":"Teaching Conservative Kidney Management and Other Palliative Care Skills in Nephrology Fellowships","authors":"Amanda K. Leonberg-Yoo MD, MS , Scott J. Gilbert MD","doi":"10.1016/j.semnephrol.2023.151396","DOIUrl":"10.1016/j.semnephrol.2023.151396","url":null,"abstract":"<div>Offering and providing effective conservative kidney management (CKM) for patients with end-stage kidney disease who do not want dialysis is a foundational skill that all nephrology fellows should learn during fellowship training. However, the current educational landscape in fellowship training programs is sparse and is not recognized currently as a skill within the Accreditation Council for Graduate Medical Education (ACGME) guidelines. Moreover, there is no standardized curriculum, methods of assessment of this learning objective, and no structure for implementation within general and subspecialty nephrology training programs. In this article, we discuss the current educational resources available for fellowship training programs, including interactive communication skills workshops such as NephroTalk, that address core concepts of CKM and assess communication skills and attitudes of trainees. Additional assessment tools should be prioritized when developing a CKM curriculum, including assessment of symptom management and medical knowledge acquisition. We propose that the ACGME nephrology milestones specifically highlight CKM as an important component within the ACGME nephrology milestones, thus ensuring that trainees understand how and when to offer CKM (knowledge), implement it effectively (skills), and conceptualize it as an appropriate course for patients in a number of varied situations (attitudes). We also outline a subspecialty pathway for palliative nephrology, to align with the recent American Society of Nephrology Task Force Recommendation to provide subspecialty training beyond core competencies, for those interested in pursuit of advanced training that ultimately can shape the CKM landscape in education and policy making.</div>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":"43 1","pages":"Article 151396"},"PeriodicalIF":3.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9987901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Onconephrology and Thrombotic Microangiopathy: Looking Beyond the Horizon 肿瘤学和血栓性微血管病:超越地平线

IF 3.3 3区医学

Seminars in nephrology Pub Date : 2022-11-01 DOI: 10.1016/j.semnephrol.2023.151345

Prakash Gudsoorkar , Ala Abudayyeh , Amanda Tchakarov , Ramy Hanna MD

{"title":"Onconephrology and Thrombotic Microangiopathy: Looking Beyond the Horizon","authors":"Prakash Gudsoorkar , Ala Abudayyeh , Amanda Tchakarov , Ramy Hanna MD","doi":"10.1016/j.semnephrol.2023.151345","DOIUrl":"10.1016/j.semnephrol.2023.151345","url":null,"abstract":"<div>Thrombotic microangiopathies (TMAs) represent a complex interaction of endothelial and podocyte biology, nephron physiology, complement genetics, and oncologic therapies with host immunology. The complexity of various factors, such as molecular causes, genetic expressions, and immune system mimicking, along with incomplete penetrance, make it difficult to find a straightforward solution. As a result, there may be variations in diagnosis, study, and treatment approaches, and achieving a consensus can be challenging. Here, we review the molecular biology, pharmacology, immunology, molecular genetics, and pathology of the various TMA syndromes in the setting of cancer. Controversies in etiology, nomenclature, and points requiring further clinical, translational, and bench research are discussed. Complement-mediated TMAs, chemotherapy drug–mediated TMAs, TMAs in monoclonal gammopathy, and other TMAs central to onconephrology practice are reviewed in detail. In addition, established and emerging therapies within the US Food and Drug Administration pipeline subsequently are discussed. Finally, a comprehensive review of critical areas of onconephrology clinical practice is presented as practical value to the clinical practitioner and seeds of investigation to be sown among the community of atypical hemolytic uremic syndrome researchers.</div>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":"42 6","pages":"Article 151345"},"PeriodicalIF":3.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9682329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Rescue Therapies for AKI in Onconephrology: Rasburicase and Glucarpidase 肾肾损伤的抢救治疗:Rasburicase和Glucarpidase

IF 3.3 3区医学

Seminars in nephrology Pub Date : 2022-11-01 DOI: 10.1016/j.semnephrol.2023.151342

Sheron Latcha MD , Chintan V. Shah MD

引用次数: 0

Updates in Plasma Cell Dyscrasias and Related Monoclonal Immunoglobulin-Mediated Renal Disease 浆细胞异常和相关单克隆免疫球蛋白介导的肾脏疾病的最新进展

IF 3.3 3区医学

Seminars in nephrology Pub Date : 2022-11-01 DOI: 10.1016/j.semnephrol.2023.151352

Shonali Midha MD , Omar Nadeem MD , Umut Selamet MD

{"title":"Updates in Plasma Cell Dyscrasias and Related Monoclonal Immunoglobulin-Mediated Renal Disease","authors":"Shonali Midha MD , Omar Nadeem MD , Umut Selamet MD","doi":"10.1016/j.semnephrol.2023.151352","DOIUrl":"10.1016/j.semnephrol.2023.151352","url":null,"abstract":"<div>Pathogenic roles of monoclonal immunoglobulins in kidney disease have been attributed previously to malignant plasma cell and lymphoproliferative disorders such as multiple myeloma, lymphoplasmacytic lymphoma, chronic lymphocytic leukemia, or amyloid light chain amyloidosis. Improved technology, advancements in molecular diagnostics, and highly sensitive imaging techniques have established the need to redefine monoclonal gammopathies and the kidney disorders that are associated with monoclonal immunoglobulins regardless of tumor burden. This has led to the establishment of monoclonal gammopathy with renal significance (MGRS). MGRS was defined by the International Kidney and Monoclonal Gammopathy Research Group in 2012 as a clonal proliferative disorder that produces a nephrotoxic monoclonal immunoglobulin and does not meet previously defined hematological criteria for treatment of a specific malignancy. MGRS encompasses a wide array of pathologies with knowledge surrounding its incidence, prognosis, and management continuously increasing. This review examines the current evidence on the diagnosis, prognosis, pathogenesis, and therapy of plasma cell dyscrasias and related MGRS.</div>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":"42 6","pages":"Article 151352"},"PeriodicalIF":3.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9691102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Introduction: Clinical Innovations in Onconephrology: What's New in 2023 导论:肿瘤学的临床创新:2023年的新动向

IF 3.3 3区医学

Seminars in nephrology Pub Date : 2022-11-01 DOI: 10.1016/j.semnephrol.2023.151350

Shruti Gupta MD, MPH (Guest Editor), Naoka Murakami MD, PhD (Guest Editor)

引用次数: 1

Advance Care Planning, Shared Decision Making, and Serious Illness Conversations in Onconephrology 在肿瘤学中预先护理计划、共同决策和严重疾病对话

IF 3.3 3区医学

Seminars in nephrology Pub Date : 2022-11-01 DOI: 10.1016/j.semnephrol.2023.151349

Amanda Jane Reich PhD, MPH , John Adam Reich MD , Paul Mathew MD

引用次数: 1

Transplant Onconephrology: An Update 移植肿瘤学:最新进展

IF 3.3 3区医学

Seminars in nephrology Pub Date : 2022-11-01 DOI: 10.1016/j.semnephrol.2023.151348

Christopher D. Blosser MD , Andrew J. Portuguese MD , Cecilia Santana , Naoka Murakami MD, PhD

引用次数: 0

Hypomagnesemia in Patients With Cancer: The Forgotten Ion 癌症患者低镁血症:被遗忘的离子

IF 3.3 3区医学

Seminars in nephrology Pub Date : 2022-11-01 DOI: 10.1016/j.semnephrol.2023.151347

Marco Bonilla MD , Biruh T. Workeneh MD, FASN , Nupur N. Uppal MD

{"title":"Hypomagnesemia in Patients With Cancer: The Forgotten Ion","authors":"Marco Bonilla MD , Biruh T. Workeneh MD, FASN , Nupur N. Uppal MD","doi":"10.1016/j.semnephrol.2023.151347","DOIUrl":"10.1016/j.semnephrol.2023.151347","url":null,"abstract":"<div>Magnesium is crucial for various cellular and enzymatic processes, yet it often is overlooked or underappreciated. Hypomagnesemia, a deficiency of magnesium in the blood, is a frequent problem in cancer patients and can lead to severe symptoms and morbidity. In this review, we provide an in-depth analysis of the physiology and regulation of magnesium, and signs and symptoms of hypomagnesemia in cancer patients. We also examine the causes and mechanisms of magnesium imbalances in cancer patients, specifically focusing on cancer-specific therapies that can lead to hypomagnesemia. Finally, we provide updates on the management of hypomagnesemia, including oral and parenteral supplementation, as well as the role of drugs in cases that are resistant to treatment. This review aims to raise awareness among health care providers caring for cancer patients about the significance of monitoring magnesium levels in cancer patients and function as a guide. Future clinical studies should focus on magnesium monitoring, its impact on cancer progression, and its potential for preventing acute kidney injury.</div>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":"42 6","pages":"Article 151347"},"PeriodicalIF":3.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9694358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Immune Checkpoint Inhibitor–Associated AKI: Debates in Diagnosis, Management, and Rechallenge 免疫检查点抑制剂相关AKI:诊断、管理和再挑战的争论

IF 3.3 3区医学

Seminars in nephrology Pub Date : 2022-11-01 DOI: 10.1016/j.semnephrol.2023.151346

Harish Seethapathy MD , Sandra M. Herrmann MD , Arash Rashidi MD

引用次数: 0

Cisplatin Nephrotoxicity: Novel Insights Into Mechanisms and Preventative Strategies 顺铂肾毒性:机制和预防策略的新见解

IF 3.3 3区医学

Seminars in nephrology Pub Date : 2022-11-01 DOI: 10.1016/j.semnephrol.2023.151341

Shveta S. Motwani MD, MMSc , Sharneet K. Sandhu MD , Abhijat Kitchlu MD, MSc

引用次数: 1